Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Drug DiscoveryCRO

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1739194

Cover Image

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1739194

Nanoparticle Contract Manufacturing

PUBLISHED:
PAGES: 194 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 5850
PDF (Global License to Company and its Fully-owned Subsidiaries)
USD 17550

Add to Cart

Description

Table of Contents

Global Nanoparticle Contract Manufacturing Market to Reach US$4.0 Billion by 2030

The global market for Nanoparticle Contract Manufacturing estimated at US$2.8 Billion in the year 2024, is expected to reach US$4.0 Billion by 2030, growing at a CAGR of 6.5% over the analysis period 2024-2030. Metal Nanoparticles, one of the segments analyzed in the report, is expected to record a 6.9% CAGR and reach US$2.6 Billion by the end of the analysis period. Growth in the Lipid Nanoparticles segment is estimated at 5.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$724.2 Million While China is Forecast to Grow at 6.4% CAGR

The Nanoparticle Contract Manufacturing market in the U.S. is estimated at US$724.2 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$646.1 Million by the year 2030 trailing a CAGR of 6.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 6.1% and 5.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.2% CAGR.

Global Nanoparticle Contract Manufacturing Market - Key Trends & Drivers Summarized

Why Is Nanoparticle Contract Manufacturing Gaining Strategic Importance Across the Biopharma and Materials Sectors?

Nanoparticle contract manufacturing has become a critical enabler in the development and commercialization of nanotechnology-based products across pharmaceuticals, biotechnology, cosmetics, and advanced materials. As nanoparticle formulations often require complex synthesis, purification, and characterization steps, outsourcing these processes to specialized contract manufacturing organizations (CMOs) provides scale, regulatory alignment, and technical expertise that many innovators lack in-house. These partnerships allow startups, academic spin-offs, and even large pharma players to accelerate product development while reducing capital expenditure on high-end nano fabrication infrastructure.

In the biopharmaceutical sector, nanoparticles are increasingly used as drug delivery vehicles-particularly in liposomal formulations, lipid nanoparticles (LNPs) for mRNA delivery, and polymer-based nanosuspensions. Their ability to enhance solubility, target delivery, control release, and bypass biological barriers has made them indispensable in oncology, vaccines, and CNS drugs. The rising complexity of these products, coupled with tight regulatory controls around particle size, morphology, and purity, has made contract manufacturers integral to the nanomedicine supply chain. Beyond pharma, industries like food, personal care, and electronics also rely on CMOs for high-precision nanoparticle production under GMP and ISO standards.

How Are Technology Platforms, Quality Systems, and Process Optimization Enhancing CMO Capabilities?

Contract manufacturers specializing in nanoparticles are investing in scalable and reproducible synthesis technologies such as microfluidics, high-pressure homogenization, emulsion-diffusion, supercritical fluid processing, and solvent evaporation. These techniques allow tight control over particle size distribution, zeta potential, encapsulation efficiency, and drug loading-key metrics for regulatory success and therapeutic performance. Continuous manufacturing platforms are also being adopted for better yield consistency and process validation, especially in high-throughput nanocarrier production.

Robust analytical capabilities are a differentiator in this space, with CMOs offering advanced particle characterization via dynamic light scattering (DLS), scanning electron microscopy (SEM), atomic force microscopy (AFM), and HPLC. Regulatory-compliant quality management systems (QMS) ensure data integrity, lot traceability, and sterility assurance for clinical and commercial batches. Some CDMOs are also integrating formulation services, aseptic fill-finish, and cold chain logistics into their nanoparticle manufacturing offerings, delivering an end-to-end solution for nanomedicine developers. This bundling of services reduces the coordination burden and regulatory complexity for sponsors.

Which Application Areas and Client Segments Are Fueling Demand for Nanoparticle Manufacturing Services?

Pharmaceutical and biotech companies account for the majority of demand, particularly those developing nanocarriers for anticancer drugs, mRNA therapeutics, gene editing tools, and long-acting injectables. The success of LNP-based COVID-19 vaccines has accelerated investment in nanoparticle platforms for nucleic acid delivery, prompting both established players and new entrants to seek contract manufacturing support. Dermatological and ophthalmic drugs are also using nanoparticles to enhance bioavailability and targeting precision.

Outside healthcare, the cosmetics industry uses nanoparticles for UV filtration, anti-aging actives, and skin absorption enhancers. Food and beverage companies are exploring nano-encapsulation for flavor preservation and nutrient fortification. Electronics and energy firms require nanoparticle solutions for batteries, coatings, and conductive inks, albeit at different scales and compliance requirements. Startups and academic labs often rely on CMOs for pilot-scale runs, feasibility studies, and regulatory documentation. As nanoparticle-enabled products diversify, demand for specialized and vertically integrated CMOs continues to grow.

What Is Driving Long-Term Growth and Differentiation in the Nanoparticle Contract Manufacturing Market?

The growth in the nanoparticle contract manufacturing market is driven by the proliferation of nano-enabled products, accelerated biotech innovation, and increasing preference for outsourcing complex and capital-intensive processes. Strategic collaborations between drug developers and CDMOs are reducing time-to-market, de-risking development pipelines, and ensuring regulatory alignment in increasingly competitive therapeutic areas. Demand is being reinforced by government funding for nanomedicine research, orphan drug designations for nanoparticle-based therapies, and rising interest in personalized nanotherapeutics.

Market differentiation is occurring through proprietary technology platforms, regulatory expertise, and the ability to support both early-phase and commercial-scale production. CMOs that can co-develop nanoparticle IP, offer formulation customization, and navigate global regulatory frameworks are especially well-positioned. Future trends include the expansion of green chemistry approaches, machine learning-driven process modeling, and modular cleanroom facilities tailored for nano-scale production. As nanoparticles become foundational to innovation across industries, contract manufacturers will play an increasingly strategic role in converting scientific potential into commercially viable products.

SCOPE OF STUDY:

The report analyzes the Nanoparticle Contract Manufacturing market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type of Nanoparticles (Metal Nanoparticles, Lipid Nanoparticles, Other Types of Nanoparticles); Manufacturing Scale (Commercial Manufacturing Scale, Clinical Manufacturing Scale, Pre-clinical Manufacturing Scale); Application (Therapeutics Application, Diagnostics Application, Vaccines Application); End-Use (Pharmaceutical Companies End-Use, Biotechnology Companies End-Use)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 32 Featured) -

  • American Elements
  • Ardena Holding NV
  • Ascendia Pharmaceuticals
  • AstraZeneca
  • AVANSA Technology & Services
  • BBI Solutions (Novacyt Group)
  • BioVectra Inc.
  • CordenPharma International GmbH
  • Cytodiagnostics Inc.
  • Encapsula NanoSciences LLC
  • Evonik Industries AG
  • Fortis Life Sciences
  • FUJIFILM Corporation
  • LSNE Contract Manufacturing
  • Merck KGaA
  • MyBiotech GmbH
  • Nano Labs Corporation
  • nanoComposix, Inc.
  • Nanoscale Corporation
  • Nanoshel LLC

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

Show more
Product Code: MCP34111

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Impact of Covid-19 and a Looming Global Recession
    • Nanoparticle Contract Manufacturing - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Growth in Nanomedicine Pipelines Drives Demand for Specialized Contract Manufacturing Services
    • Rise in Targeted Drug Delivery Systems Spurs Adoption of Nanoparticle Formulations
    • Expansion of mRNA and Nucleic Acid-Based Therapeutics Strengthens Business Case for Lipid Nanoparticles
    • Outsourcing Trend in Pharma and Biotech Boosts Demand for End-to-End Nanoparticle CDMO Solutions
    • Emergence of Personalized Nanomedicine Expands Addressable Market for Custom Particle Engineering
    • Increased Complexity in Regulatory Filings Throws the Spotlight on GMP-Compliant CDMOs
    • Collaborative Drug Development Models Propel Growth in Specialized Manufacturing Partnerships
    • Rapid Commercialization of RNA-Based Vaccines Drives Demand for Scalable Nanoparticle Production
    • Innovation in Polymer and Lipid Nanoparticles Enhances Customization Potential
    • Proliferation of Oncology Nanotherapeutics Fuels Growth in High-Precision Contract Manufacturing
    • Investment in Containment and Sterile Facilities Strengthens Capabilities of Leading CDMOs
    • Surging Need for Small-Batch Clinical Manufacturing Drives Flexibility in CDMO Offerings
    • Integration of Process Analytical Technology (PAT) Enables Real-Time Particle Size Control
    • Global Regulatory Harmonization Efforts Simplify Cross-Border Market Entry for Contract Manufacturers
    • Application of AI and ML in Process Design Supports Optimization and Cost Reduction
    • Increasing Use of Nanoparticles in Cosmetics and Nutraceuticals Broadens End-User Base
    • Establishment of Nano Innovation Hubs and Tech Transfer Centers Spurs Regional CDMO Expansion
    • Demand for Surface Functionalization Services Generates Differentiation Opportunities
    • Rising Emphasis on Sustainable Nanoparticle Synthesis Presents Greener Manufacturing Avenues
    • Shortage of Specialized Talent and Equipment Poses Scalability Challenges for Smaller CDMOs
    • Strategic Alliances Between Pharma Giants and Specialized CDMOs Propel Innovation in Delivery Platforms
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Nanoparticle Contract Manufacturing Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Nanoparticle Contract Manufacturing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World 6-Year Perspective for Nanoparticle Contract Manufacturing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Metal Nanoparticles by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 5: World 6-Year Perspective for Metal Nanoparticles by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 6: World Recent Past, Current & Future Analysis for Lipid Nanoparticles by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 7: World 6-Year Perspective for Lipid Nanoparticles by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Other Types of Nanoparticles by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World 6-Year Perspective for Other Types of Nanoparticles by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Pharmaceutical Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 11: World 6-Year Perspective for Pharmaceutical Companies End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 12: World Recent Past, Current & Future Analysis for Biotechnology Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 13: World 6-Year Perspective for Biotechnology Companies End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Commercial Manufacturing Scale by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World 6-Year Perspective for Commercial Manufacturing Scale by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Clinical Manufacturing Scale by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 17: World 6-Year Perspective for Clinical Manufacturing Scale by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 18: World Recent Past, Current & Future Analysis for Pre-clinical Manufacturing Scale by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 19: World 6-Year Perspective for Pre-clinical Manufacturing Scale by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Therapeutics Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World 6-Year Perspective for Therapeutics Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Diagnostics Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 23: World 6-Year Perspective for Diagnostics Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 24: World Recent Past, Current & Future Analysis for Vaccines Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 25: World 6-Year Perspective for Vaccines Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Nanoparticle Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 26: USA Recent Past, Current & Future Analysis for Nanoparticle Contract Manufacturing by Type of Nanoparticles - Metal Nanoparticles, Lipid Nanoparticles and Other Types of Nanoparticles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA 6-Year Perspective for Nanoparticle Contract Manufacturing by Type of Nanoparticles - Percentage Breakdown of Value Sales for Metal Nanoparticles, Lipid Nanoparticles and Other Types of Nanoparticles for the Years 2025 & 2030
    • TABLE 28: USA Recent Past, Current & Future Analysis for Nanoparticle Contract Manufacturing by End-Use - Pharmaceutical Companies End-Use and Biotechnology Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 29: USA 6-Year Perspective for Nanoparticle Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use and Biotechnology Companies End-Use for the Years 2025 & 2030
    • TABLE 30: USA Recent Past, Current & Future Analysis for Nanoparticle Contract Manufacturing by Manufacturing Scale - Commercial Manufacturing Scale, Clinical Manufacturing Scale and Pre-clinical Manufacturing Scale - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 31: USA 6-Year Perspective for Nanoparticle Contract Manufacturing by Manufacturing Scale - Percentage Breakdown of Value Sales for Commercial Manufacturing Scale, Clinical Manufacturing Scale and Pre-clinical Manufacturing Scale for the Years 2025 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Nanoparticle Contract Manufacturing by Application - Therapeutics Application, Diagnostics Application and Vaccines Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA 6-Year Perspective for Nanoparticle Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Therapeutics Application, Diagnostics Application and Vaccines Application for the Years 2025 & 2030
  • CANADA
    • TABLE 34: Canada Recent Past, Current & Future Analysis for Nanoparticle Contract Manufacturing by Type of Nanoparticles - Metal Nanoparticles, Lipid Nanoparticles and Other Types of Nanoparticles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 35: Canada 6-Year Perspective for Nanoparticle Contract Manufacturing by Type of Nanoparticles - Percentage Breakdown of Value Sales for Metal Nanoparticles, Lipid Nanoparticles and Other Types of Nanoparticles for the Years 2025 & 2030
    • TABLE 36: Canada Recent Past, Current & Future Analysis for Nanoparticle Contract Manufacturing by End-Use - Pharmaceutical Companies End-Use and Biotechnology Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 37: Canada 6-Year Perspective for Nanoparticle Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use and Biotechnology Companies End-Use for the Years 2025 & 2030
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Nanoparticle Contract Manufacturing by Manufacturing Scale - Commercial Manufacturing Scale, Clinical Manufacturing Scale and Pre-clinical Manufacturing Scale - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada 6-Year Perspective for Nanoparticle Contract Manufacturing by Manufacturing Scale - Percentage Breakdown of Value Sales for Commercial Manufacturing Scale, Clinical Manufacturing Scale and Pre-clinical Manufacturing Scale for the Years 2025 & 2030
    • TABLE 40: Canada Recent Past, Current & Future Analysis for Nanoparticle Contract Manufacturing by Application - Therapeutics Application, Diagnostics Application and Vaccines Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 41: Canada 6-Year Perspective for Nanoparticle Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Therapeutics Application, Diagnostics Application and Vaccines Application for the Years 2025 & 2030
  • JAPAN
    • Nanoparticle Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 42: Japan Recent Past, Current & Future Analysis for Nanoparticle Contract Manufacturing by Type of Nanoparticles - Metal Nanoparticles, Lipid Nanoparticles and Other Types of Nanoparticles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 43: Japan 6-Year Perspective for Nanoparticle Contract Manufacturing by Type of Nanoparticles - Percentage Breakdown of Value Sales for Metal Nanoparticles, Lipid Nanoparticles and Other Types of Nanoparticles for the Years 2025 & 2030
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Nanoparticle Contract Manufacturing by End-Use - Pharmaceutical Companies End-Use and Biotechnology Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Japan 6-Year Perspective for Nanoparticle Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use and Biotechnology Companies End-Use for the Years 2025 & 2030
    • TABLE 46: Japan Recent Past, Current & Future Analysis for Nanoparticle Contract Manufacturing by Manufacturing Scale - Commercial Manufacturing Scale, Clinical Manufacturing Scale and Pre-clinical Manufacturing Scale - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 47: Japan 6-Year Perspective for Nanoparticle Contract Manufacturing by Manufacturing Scale - Percentage Breakdown of Value Sales for Commercial Manufacturing Scale, Clinical Manufacturing Scale and Pre-clinical Manufacturing Scale for the Years 2025 & 2030
    • TABLE 48: Japan Recent Past, Current & Future Analysis for Nanoparticle Contract Manufacturing by Application - Therapeutics Application, Diagnostics Application and Vaccines Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 49: Japan 6-Year Perspective for Nanoparticle Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Therapeutics Application, Diagnostics Application and Vaccines Application for the Years 2025 & 2030
  • CHINA
    • Nanoparticle Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 50: China Recent Past, Current & Future Analysis for Nanoparticle Contract Manufacturing by Type of Nanoparticles - Metal Nanoparticles, Lipid Nanoparticles and Other Types of Nanoparticles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: China 6-Year Perspective for Nanoparticle Contract Manufacturing by Type of Nanoparticles - Percentage Breakdown of Value Sales for Metal Nanoparticles, Lipid Nanoparticles and Other Types of Nanoparticles for the Years 2025 & 2030
    • TABLE 52: China Recent Past, Current & Future Analysis for Nanoparticle Contract Manufacturing by End-Use - Pharmaceutical Companies End-Use and Biotechnology Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 53: China 6-Year Perspective for Nanoparticle Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use and Biotechnology Companies End-Use for the Years 2025 & 2030
    • TABLE 54: China Recent Past, Current & Future Analysis for Nanoparticle Contract Manufacturing by Manufacturing Scale - Commercial Manufacturing Scale, Clinical Manufacturing Scale and Pre-clinical Manufacturing Scale - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 55: China 6-Year Perspective for Nanoparticle Contract Manufacturing by Manufacturing Scale - Percentage Breakdown of Value Sales for Commercial Manufacturing Scale, Clinical Manufacturing Scale and Pre-clinical Manufacturing Scale for the Years 2025 & 2030
    • TABLE 56: China Recent Past, Current & Future Analysis for Nanoparticle Contract Manufacturing by Application - Therapeutics Application, Diagnostics Application and Vaccines Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: China 6-Year Perspective for Nanoparticle Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Therapeutics Application, Diagnostics Application and Vaccines Application for the Years 2025 & 2030
  • EUROPE
    • Nanoparticle Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 58: Europe Recent Past, Current & Future Analysis for Nanoparticle Contract Manufacturing by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 59: Europe 6-Year Perspective for Nanoparticle Contract Manufacturing by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
    • TABLE 60: Europe Recent Past, Current & Future Analysis for Nanoparticle Contract Manufacturing by Type of Nanoparticles - Metal Nanoparticles, Lipid Nanoparticles and Other Types of Nanoparticles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 61: Europe 6-Year Perspective for Nanoparticle Contract Manufacturing by Type of Nanoparticles - Percentage Breakdown of Value Sales for Metal Nanoparticles, Lipid Nanoparticles and Other Types of Nanoparticles for the Years 2025 & 2030
    • TABLE 62: Europe Recent Past, Current & Future Analysis for Nanoparticle Contract Manufacturing by End-Use - Pharmaceutical Companies End-Use and Biotechnology Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Europe 6-Year Perspective for Nanoparticle Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use and Biotechnology Companies End-Use for the Years 2025 & 2030
    • TABLE 64: Europe Recent Past, Current & Future Analysis for Nanoparticle Contract Manufacturing by Manufacturing Scale - Commercial Manufacturing Scale, Clinical Manufacturing Scale and Pre-clinical Manufacturing Scale - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 65: Europe 6-Year Perspective for Nanoparticle Contract Manufacturing by Manufacturing Scale - Percentage Breakdown of Value Sales for Commercial Manufacturing Scale, Clinical Manufacturing Scale and Pre-clinical Manufacturing Scale for the Years 2025 & 2030
    • TABLE 66: Europe Recent Past, Current & Future Analysis for Nanoparticle Contract Manufacturing by Application - Therapeutics Application, Diagnostics Application and Vaccines Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 67: Europe 6-Year Perspective for Nanoparticle Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Therapeutics Application, Diagnostics Application and Vaccines Application for the Years 2025 & 2030
  • FRANCE
    • Nanoparticle Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 68: France Recent Past, Current & Future Analysis for Nanoparticle Contract Manufacturing by Type of Nanoparticles - Metal Nanoparticles, Lipid Nanoparticles and Other Types of Nanoparticles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: France 6-Year Perspective for Nanoparticle Contract Manufacturing by Type of Nanoparticles - Percentage Breakdown of Value Sales for Metal Nanoparticles, Lipid Nanoparticles and Other Types of Nanoparticles for the Years 2025 & 2030
    • TABLE 70: France Recent Past, Current & Future Analysis for Nanoparticle Contract Manufacturing by End-Use - Pharmaceutical Companies End-Use and Biotechnology Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 71: France 6-Year Perspective for Nanoparticle Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use and Biotechnology Companies End-Use for the Years 2025 & 2030
    • TABLE 72: France Recent Past, Current & Future Analysis for Nanoparticle Contract Manufacturing by Manufacturing Scale - Commercial Manufacturing Scale, Clinical Manufacturing Scale and Pre-clinical Manufacturing Scale - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 73: France 6-Year Perspective for Nanoparticle Contract Manufacturing by Manufacturing Scale - Percentage Breakdown of Value Sales for Commercial Manufacturing Scale, Clinical Manufacturing Scale and Pre-clinical Manufacturing Scale for the Years 2025 & 2030
    • TABLE 74: France Recent Past, Current & Future Analysis for Nanoparticle Contract Manufacturing by Application - Therapeutics Application, Diagnostics Application and Vaccines Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: France 6-Year Perspective for Nanoparticle Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Therapeutics Application, Diagnostics Application and Vaccines Application for the Years 2025 & 2030
  • GERMANY
    • Nanoparticle Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 76: Germany Recent Past, Current & Future Analysis for Nanoparticle Contract Manufacturing by Type of Nanoparticles - Metal Nanoparticles, Lipid Nanoparticles and Other Types of Nanoparticles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 77: Germany 6-Year Perspective for Nanoparticle Contract Manufacturing by Type of Nanoparticles - Percentage Breakdown of Value Sales for Metal Nanoparticles, Lipid Nanoparticles and Other Types of Nanoparticles for the Years 2025 & 2030
    • TABLE 78: Germany Recent Past, Current & Future Analysis for Nanoparticle Contract Manufacturing by End-Use - Pharmaceutical Companies End-Use and Biotechnology Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 79: Germany 6-Year Perspective for Nanoparticle Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use and Biotechnology Companies End-Use for the Years 2025 & 2030
    • TABLE 80: Germany Recent Past, Current & Future Analysis for Nanoparticle Contract Manufacturing by Manufacturing Scale - Commercial Manufacturing Scale, Clinical Manufacturing Scale and Pre-clinical Manufacturing Scale - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Germany 6-Year Perspective for Nanoparticle Contract Manufacturing by Manufacturing Scale - Percentage Breakdown of Value Sales for Commercial Manufacturing Scale, Clinical Manufacturing Scale and Pre-clinical Manufacturing Scale for the Years 2025 & 2030
    • TABLE 82: Germany Recent Past, Current & Future Analysis for Nanoparticle Contract Manufacturing by Application - Therapeutics Application, Diagnostics Application and Vaccines Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 83: Germany 6-Year Perspective for Nanoparticle Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Therapeutics Application, Diagnostics Application and Vaccines Application for the Years 2025 & 2030
  • ITALY
    • TABLE 84: Italy Recent Past, Current & Future Analysis for Nanoparticle Contract Manufacturing by Type of Nanoparticles - Metal Nanoparticles, Lipid Nanoparticles and Other Types of Nanoparticles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 85: Italy 6-Year Perspective for Nanoparticle Contract Manufacturing by Type of Nanoparticles - Percentage Breakdown of Value Sales for Metal Nanoparticles, Lipid Nanoparticles and Other Types of Nanoparticles for the Years 2025 & 2030
    • TABLE 86: Italy Recent Past, Current & Future Analysis for Nanoparticle Contract Manufacturing by End-Use - Pharmaceutical Companies End-Use and Biotechnology Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Italy 6-Year Perspective for Nanoparticle Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use and Biotechnology Companies End-Use for the Years 2025 & 2030
    • TABLE 88: Italy Recent Past, Current & Future Analysis for Nanoparticle Contract Manufacturing by Manufacturing Scale - Commercial Manufacturing Scale, Clinical Manufacturing Scale and Pre-clinical Manufacturing Scale - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 89: Italy 6-Year Perspective for Nanoparticle Contract Manufacturing by Manufacturing Scale - Percentage Breakdown of Value Sales for Commercial Manufacturing Scale, Clinical Manufacturing Scale and Pre-clinical Manufacturing Scale for the Years 2025 & 2030
    • TABLE 90: Italy Recent Past, Current & Future Analysis for Nanoparticle Contract Manufacturing by Application - Therapeutics Application, Diagnostics Application and Vaccines Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 91: Italy 6-Year Perspective for Nanoparticle Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Therapeutics Application, Diagnostics Application and Vaccines Application for the Years 2025 & 2030
  • UNITED KINGDOM
    • Nanoparticle Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 92: UK Recent Past, Current & Future Analysis for Nanoparticle Contract Manufacturing by Type of Nanoparticles - Metal Nanoparticles, Lipid Nanoparticles and Other Types of Nanoparticles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: UK 6-Year Perspective for Nanoparticle Contract Manufacturing by Type of Nanoparticles - Percentage Breakdown of Value Sales for Metal Nanoparticles, Lipid Nanoparticles and Other Types of Nanoparticles for the Years 2025 & 2030
    • TABLE 94: UK Recent Past, Current & Future Analysis for Nanoparticle Contract Manufacturing by End-Use - Pharmaceutical Companies End-Use and Biotechnology Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 95: UK 6-Year Perspective for Nanoparticle Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use and Biotechnology Companies End-Use for the Years 2025 & 2030
    • TABLE 96: UK Recent Past, Current & Future Analysis for Nanoparticle Contract Manufacturing by Manufacturing Scale - Commercial Manufacturing Scale, Clinical Manufacturing Scale and Pre-clinical Manufacturing Scale - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 97: UK 6-Year Perspective for Nanoparticle Contract Manufacturing by Manufacturing Scale - Percentage Breakdown of Value Sales for Commercial Manufacturing Scale, Clinical Manufacturing Scale and Pre-clinical Manufacturing Scale for the Years 2025 & 2030
    • TABLE 98: UK Recent Past, Current & Future Analysis for Nanoparticle Contract Manufacturing by Application - Therapeutics Application, Diagnostics Application and Vaccines Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: UK 6-Year Perspective for Nanoparticle Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Therapeutics Application, Diagnostics Application and Vaccines Application for the Years 2025 & 2030
  • REST OF EUROPE
    • TABLE 100: Rest of Europe Recent Past, Current & Future Analysis for Nanoparticle Contract Manufacturing by Type of Nanoparticles - Metal Nanoparticles, Lipid Nanoparticles and Other Types of Nanoparticles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 101: Rest of Europe 6-Year Perspective for Nanoparticle Contract Manufacturing by Type of Nanoparticles - Percentage Breakdown of Value Sales for Metal Nanoparticles, Lipid Nanoparticles and Other Types of Nanoparticles for the Years 2025 & 2030
    • TABLE 102: Rest of Europe Recent Past, Current & Future Analysis for Nanoparticle Contract Manufacturing by End-Use - Pharmaceutical Companies End-Use and Biotechnology Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 103: Rest of Europe 6-Year Perspective for Nanoparticle Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use and Biotechnology Companies End-Use for the Years 2025 & 2030
    • TABLE 104: Rest of Europe Recent Past, Current & Future Analysis for Nanoparticle Contract Manufacturing by Manufacturing Scale - Commercial Manufacturing Scale, Clinical Manufacturing Scale and Pre-clinical Manufacturing Scale - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Rest of Europe 6-Year Perspective for Nanoparticle Contract Manufacturing by Manufacturing Scale - Percentage Breakdown of Value Sales for Commercial Manufacturing Scale, Clinical Manufacturing Scale and Pre-clinical Manufacturing Scale for the Years 2025 & 2030
    • TABLE 106: Rest of Europe Recent Past, Current & Future Analysis for Nanoparticle Contract Manufacturing by Application - Therapeutics Application, Diagnostics Application and Vaccines Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 107: Rest of Europe 6-Year Perspective for Nanoparticle Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Therapeutics Application, Diagnostics Application and Vaccines Application for the Years 2025 & 2030
  • ASIA-PACIFIC
    • Nanoparticle Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 108: Asia-Pacific Recent Past, Current & Future Analysis for Nanoparticle Contract Manufacturing by Type of Nanoparticles - Metal Nanoparticles, Lipid Nanoparticles and Other Types of Nanoparticles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 109: Asia-Pacific 6-Year Perspective for Nanoparticle Contract Manufacturing by Type of Nanoparticles - Percentage Breakdown of Value Sales for Metal Nanoparticles, Lipid Nanoparticles and Other Types of Nanoparticles for the Years 2025 & 2030
    • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Nanoparticle Contract Manufacturing by End-Use - Pharmaceutical Companies End-Use and Biotechnology Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Asia-Pacific 6-Year Perspective for Nanoparticle Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use and Biotechnology Companies End-Use for the Years 2025 & 2030
    • TABLE 112: Asia-Pacific Recent Past, Current & Future Analysis for Nanoparticle Contract Manufacturing by Manufacturing Scale - Commercial Manufacturing Scale, Clinical Manufacturing Scale and Pre-clinical Manufacturing Scale - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 113: Asia-Pacific 6-Year Perspective for Nanoparticle Contract Manufacturing by Manufacturing Scale - Percentage Breakdown of Value Sales for Commercial Manufacturing Scale, Clinical Manufacturing Scale and Pre-clinical Manufacturing Scale for the Years 2025 & 2030
    • TABLE 114: Asia-Pacific Recent Past, Current & Future Analysis for Nanoparticle Contract Manufacturing by Application - Therapeutics Application, Diagnostics Application and Vaccines Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 115: Asia-Pacific 6-Year Perspective for Nanoparticle Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Therapeutics Application, Diagnostics Application and Vaccines Application for the Years 2025 & 2030
  • REST OF WORLD
    • TABLE 116: Rest of World Recent Past, Current & Future Analysis for Nanoparticle Contract Manufacturing by Type of Nanoparticles - Metal Nanoparticles, Lipid Nanoparticles and Other Types of Nanoparticles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Rest of World 6-Year Perspective for Nanoparticle Contract Manufacturing by Type of Nanoparticles - Percentage Breakdown of Value Sales for Metal Nanoparticles, Lipid Nanoparticles and Other Types of Nanoparticles for the Years 2025 & 2030
    • TABLE 118: Rest of World Recent Past, Current & Future Analysis for Nanoparticle Contract Manufacturing by End-Use - Pharmaceutical Companies End-Use and Biotechnology Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 119: Rest of World 6-Year Perspective for Nanoparticle Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use and Biotechnology Companies End-Use for the Years 2025 & 2030
    • TABLE 120: Rest of World Recent Past, Current & Future Analysis for Nanoparticle Contract Manufacturing by Manufacturing Scale - Commercial Manufacturing Scale, Clinical Manufacturing Scale and Pre-clinical Manufacturing Scale - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 121: Rest of World 6-Year Perspective for Nanoparticle Contract Manufacturing by Manufacturing Scale - Percentage Breakdown of Value Sales for Commercial Manufacturing Scale, Clinical Manufacturing Scale and Pre-clinical Manufacturing Scale for the Years 2025 & 2030
    • TABLE 122: Rest of World Recent Past, Current & Future Analysis for Nanoparticle Contract Manufacturing by Application - Therapeutics Application, Diagnostics Application and Vaccines Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Rest of World 6-Year Perspective for Nanoparticle Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Therapeutics Application, Diagnostics Application and Vaccines Application for the Years 2025 & 2030

IV. COMPETITION

Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!